Tradename | Company | Number | Date | Products |
---|---|---|---|---|
THEELIN | Parkedale Pharmaceuticals | N-003977 DISCN | 1982-01-01 | 3 products |
Code | Description |
---|---|
J1435 | Injection, estrone, per 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Infertility | D007246 | EFO_0000545 | — | 24 | 29 | 47 | 69 | 99 | 257 |
Female infertility | D007247 | EFO_0008560 | N97 | 12 | 6 | 7 | 8 | 31 | 60 |
Contraception | D003267 | — | — | 8 | 9 | 18 | 15 | 5 | 54 |
Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 3 | 3 | 7 | 7 | 28 | 47 |
Syndrome | D013577 | — | — | 3 | 6 | 7 | 6 | 23 | 44 |
Healthy volunteers/patients | — | — | — | 33 | 1 | 4 | 1 | 4 | 42 |
Fertilization in vitro | D005307 | — | — | 1 | 3 | 3 | 12 | 10 | 28 |
Ovulation induction | D010062 | — | — | 3 | 7 | 5 | 4 | 6 | 24 |
Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | 5 | 4 | 2 | 1 | 11 | 20 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | 4 | 2 | 1 | 8 | 17 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Endometriosis | D004715 | EFO_0001065 | N80 | 2 | 1 | 2 | — | 13 | 17 |
Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 1 | — | 10 | 11 |
Neoplasms | D009369 | — | C80 | 5 | 1 | 1 | — | 2 | 8 |
Lymphoma | D008223 | — | C85.9 | 3 | 4 | 1 | — | 2 | 8 |
Thyroid diseases | D013959 | — | E00-E07 | 1 | 4 | 2 | — | — | 7 |
Pituitary diseases | D010900 | — | E23.7 | — | 1 | 3 | — | 3 | 7 |
Premenstrual syndrome | D011293 | — | N94.3 | — | 2 | 4 | — | 1 | 7 |
Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 4 | 2 | — | — | 6 |
Male infertility | D007248 | EFO_0004248 | N46 | — | 1 | 1 | — | 4 | 5 |
Prostatic neoplasms | D011471 | — | C61 | 2 | 1 | 1 | — | 1 | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Ovarian reserve | D065851 | EFO_0004770 | — | — | 1 | — | — | 5 | 6 |
Metrorrhagia | D008796 | — | N92.1 | — | 3 | — | — | 1 | 4 |
Papillary thyroid cancer | D000077273 | — | — | — | 3 | — | — | — | 3 |
Follicular adenocarcinoma | D018263 | — | — | — | 3 | — | — | — | 3 |
Leiomyoma | D007889 | — | D25 | 1 | 1 | — | — | 2 | 3 |
Carcinoma | D002277 | — | C80.0 | 1 | 3 | — | — | — | 3 |
Hemostasis | D006487 | — | — | — | 1 | — | — | 1 | 2 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 2 | — | — | — | 2 |
Ovarian diseases | D010049 | — | — | — | 1 | — | — | 1 | 2 |
Hodgkin disease | D006689 | — | C81 | 1 | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Therapeutic equivalency | D013810 | — | — | 9 | — | — | — | — | 9 |
Pharmacokinetics | D010599 | — | — | 5 | — | — | — | — | 5 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | — | — | — | 3 | 4 |
Drug interactions | D004347 | — | — | 4 | — | — | — | — | 4 |
Hiv | D006678 | — | O98.7 | 1 | — | — | — | 2 | 3 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 3 | — | — | — | — | 3 |
Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 3 | — | — | — | — | 3 |
Fibrosis | D005355 | — | — | 2 | — | — | — | 1 | 3 |
Cystic fibrosis | D003550 | EFO_0000390 | E84 | 2 | — | — | — | 1 | 3 |
Overweight | D050177 | — | E66.3 | 2 | — | — | — | 1 | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Menstrual cycle | D008597 | — | — | — | — | — | — | 6 | 6 |
Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 6 | 6 |
Fertility | D005298 | — | — | — | — | — | — | 5 | 5 |
Ovarian cysts | D010048 | — | N83.1 | — | — | — | — | 3 | 3 |
Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 3 | 3 |
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 3 | 3 |
Oxidative stress | D018384 | EFO_1001905 | — | — | — | — | — | 3 | 3 |
Sclerosis | D012598 | — | — | — | — | — | — | 2 | 2 |
In vitro oocyte maturation techniques | D059471 | — | — | — | — | — | — | 2 | 2 |
Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | — | — | — | 2 | 2 |
Drug common name | Estrone |
INN | estrone |
Description | Estrone is a 17-oxo steroid that is estra-1,3,5(10)-triene substituted by an hydroxy group at position 3 and an oxo group at position 17. It has a role as an estrogen, a bone density conservation agent, an antineoplastic agent, a human metabolite and a mouse metabolite. It is a 3-hydroxy steroid, a phenolic steroid, a member of phenols and a 17-oxo steroid. It derives from a hydride of an estrane. |
Classification | Small molecule |
Drug class | estrogens |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O |
PDB | — |
CAS-ID | 53-16-7 |
RxCUI | — |
ChEMBL ID | CHEMBL1405 |
ChEBI ID | 17263 |
PubChem CID | 5870 |
DrugBank | DB00655 |
UNII ID | 2DI9HA706A (ChemIDplus, GSRS) |